You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 141 No. 10, October 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Burns
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Therapeutic Efficacy of Edaravone in Extensively Burned Rats

Takeo Koizumi, MD; Hideharu Tanaka, MD, PhD; Seiki Sakaki, MD; Shuji Shimazaki, MD, PhD

Arch Surg. 2006;141:992-995.

Background  Extensive burn injury leads to production of free radicals subsequent to massive fluid resuscitation, which in turn increases the risk of acute lung injury. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, is clinically effective in improving the prognosis after cerebral infarction. However, the effect of edaravone against extensive burn injury has not been tested.

Objected  To evaluate whether edaravone can reduce free radical precursors in a 30% burn model in rats.

Design  Prospective, randomized controlled experiment.

Setting  Animal basic science laboratory.

Subjects  Male Wistar rats weighing 200 to 220 g.

Main Outcome Measures  All rats (n = 10) were given a 30% full-thickness burn according to the Walker and Mason method. Immediately after the burn, edaravone was injected into the rats (n = 5) intraperitoneally at a dose of 9 mg/kg. One hour after burn injury, blood and tissue samples were collected to analyze free radical changes of serum and tissue malondialdehyde (MDA) and xanthine oxidase (XOD) and lung white blood cells.

Results  Statistical significance was found between nontreatment and edaravone treatment relative to serum MDA (mean ± SD, 2.50 ± 0.54 vs 1.74 ± 0.29 nmol/mL), serum XOD (mean ± SD, 5.04 ± 1.67 vs 2.26 ± 0.83 U/L), tissue MDA (mean ± SD, 1268.7 ± 289.9 vs 569.1 ± 135.9 nmol/mg protein), tissue XOD (mean ± SD, 256.3 ± 58.1 vs 50.96 ± 19.60 mU/g tissue), lung white blood cells (mean ± SD, 3088 ± 1144 vs 1542 ± 575 mU/g tissue), and lung XOD (mean ± SD, 428.3 ± 210.5 vs 81.8 ± 36.0 nmol/mg protein).

Conclusions  Edaravone treatment induces significant reduction of free radical precursors and their metabolites compared with controls in burn rats. This suggests that edaravone could be helpful in the clinical treatment of large burns.


Author Affiliations: Department of Emergency and Critical Care Medicine, Medical School of Kyorin University (Drs Koizumi, Sakaki, and Shimazaki), and Department of Sports Medicine, Kokushikan University (Dr Tanaka), Tokyo, Japan.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.